Health · 35 views
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease…
AI Summary
Treatment with the monoclonal antibody ziltivekimab lowered inflammatory markers in patients who have both atherosclerotic cardiovascular disease and chronic kidney disease. However, the therapy failed to reduce cardiovascular events in this population.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Night-shift work linked to differences in heart structure and biomarkersContinue reading
- Lawyer calls for urgent review of Letby convictions after expert witness revelationsContinue reading
- Sanders’ ‘Medicare for All’ plan accrues more liberate and moderate support in CongressContinue reading
- US loses measles elimination status as knowledge gaps about disease and vaccine persistContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow